About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00668525

Escitalopram in Adult Patients With Major Depressive Disorder

This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the stud...

Lead sponsor: Forest Laboratories•45 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Forest Laboratories

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients must meet Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder.
•The patient's current depressive episode must be at least 8 weeks in duration.

Exclusion Criteria

•Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.
•Patients with a history of meeting DSM-IV-TR criteria for: a. any manic or hypomanic episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive disorder.
•Patients who are considered a suicide risk
•Patients with a history of seizures (including seizure disorder), stroke, significant head injury, central nervous system tumors, or any other condition that predisposes patients to a risk for seizure.

Related studies

RECRUITINGPhase 2

Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

NCT07523048 · Major Depressive Disorder (MDD)

RECRUITINGPhase 2

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661 · Major Depressive Disorder (MDD)

RECRUITINGPhase 2

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329 · Major Depressive Disorder

RECRUITINGPhase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397 · Major Depressive Disorder (MDD), Depression in Adults, and more

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

NCT07025720 · Major Depressive Disorder (MDD), Suicidal Ideation

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 11, 2010Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment877

Start dateApr 2008

Last updatedMay 11, 2010

Condition

Major Depressive Disorder

Locations shown

Forest Investigative Site

Phoenix, Arizona

Forest Investigative Site

Arcadia, California

Forest Investigative Site

Encino, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2010Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions